Obinutuzumab

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more

August 30, 2017August 30, 2017

FDA to Review Gazyva as First-Line Treatment for Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics license application (sBLA) seeking the approval of Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone, for patients with previously untreated ... Read more

August 18, 2016August 18, 2016

Gazyva Combination Effective Therapy for NHL Patients Refractory to Rituxan

News

Results from the Phase 3 GADOLIN trial reveal that combining Gazyva (obinutuzumab) with bendamustine (available as Bendeka and Treanda) in patients with indolent non-Hodgkin’s lymphoma who are not responding to ... Read more

July 19, 2016July 19, 2016

Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study

News

Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) given Gazyva/Gazyvaro (obinutuzumab) plus standard chemotherapy (CHOP) do not have higher progression-free survival rates than those treated with Rituxan/MabThera (rituximab), according to new data ... Read more

July 6, 2016July 6, 2016

Non-Hodgkin Lymphoma Shows Significantly Better Outcomes with Obinutuzumab, Bendamustine Combo

News

Patients with non-Hodgkin lymphoma (NHL) who are resistant to rituximab therapies show greater benefits when treated with a obinutuzumab and bendamustine combination, compared to the standard bendamustine alone, according to data from the ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more

March 1, 2016May 13, 2016

FDA Approves Gazyva as Combo Treatment for Follicular Lymphomas Unresponsive to Rituxan

News

Genentech announced that the the U.S. Food and Drug Administration (FDA) has approved the combination of Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva for the treatment of people with follicular lymphoma who were ... Read more